Since AR signaling persists in most cases of CRPC, patients receive further treatment with AR signaling inhibitors (abiraterone acetate, enzalutamide, apalutamide, and darolutamide) based on whether they have metastatic or non-metastatic disease (9–12). This evidence concerns the gene AR and metastatic neoplasm.